Please login to the form below

Not currently logged in
Email:
Password:

Inlyta

This page shows the latest Inlyta news and features for those working in and with pharma, biotech and healthcare.

Pfizer's 2021 revenue predictions soar to $82bn

Pfizer's 2021 revenue predictions soar to $82bn

In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased

Latest news

More from news
Approximately 7 fully matching, plus 40 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it ... The JAVELIN Renal 101 trial combining Bavencio with Inlyta in

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    Back then, the UK’s cost-effectiveness watchdog NICE  deemed Opdivo too pricey for renal cell carcinoma when taking into account the availability of Pfizer's Inlyta at a markedly lower

  • Oncology drugs under AMNOG

    A benefit was found for Inlyta compared with Nexavar in the cytokine treatment group, on the basis of increased tolerability. ... of benefit in one category for these patients was enough to send Inlyta to negotiations for pricing.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Genetic Digital

Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....